Bengaluru, Karnataka, India, March 2026 – Biocon Limited has announced the appointment of Kedar Upadhye as Chief Financial Officer, marking a significant addition to its leadership team as the company continues to strengthen its global footprint in the biopharmaceutical space. With extensive experience across finance leadership, investor relations, and global business strategy, Kedar brings deep expertise in driving financial excellence and supporting large-scale growth organizations.
Prior to this role, Kedar Upadhye served as Chief Financial Officer at Biocon Biologics, where he has been leading financial strategy and operations for over two years. In this role, he has been closely associated with advancing the company’s biosimilars business globally, supporting strategic growth initiatives and strengthening financial governance.
Before joining Biocon, he was the Group Chief Financial Officer at ReNew Power, where he played a key role in steering financial strategy for one of India’s leading renewable energy companies. His tenure involved strengthening financial performance and supporting the organization’s growth trajectory in a rapidly evolving energy landscape.
Earlier, Kedar held senior leadership roles at Cipla, including President, Global CFO & Head of IT and Joint President & Global CFO, where he spent several years driving global finance transformation, managing investor relations, and aligning financial strategy with business growth across international markets.
He also spent over a decade with Dr. Reddy’s Laboratories, where he held multiple leadership roles including Vice President and Head, Global Generics Finance and Investor Relations and Director, Corporate Finance & Investor Relations. During this period, he led financial planning, investor relations, and analytics functions, contributing significantly to the company’s global generics business and financial strategy.
Kedar began his professional journey with PepsiCo, where he worked in financial analysis and reporting, gaining early exposure to corporate finance in a global organization. He holds a management degree from the Indian Institute of Management Bangalore, further strengthening his strong foundation in finance and strategy.
Biocon Limited (BSE: 532523) (NSE: BIOCON) is a global biopharmaceutical company driven by its purpose to provide affordable, life-changing medicines to patients worldwide. Headquartered in Bengaluru, India, the company addresses some of the world’s most pressing healthcare challenges across chronic and non-communicable diseases through its portfolio of biosimilars and generics.
Biocon operates across more than 120 countries and focuses on key therapy areas including diabetes, oncology, obesity, cardiovascular diseases, immunology, ophthalmology, and bone health. The company has commercialized 12 biosimilars and over 30 generic formulations globally and continues to advance a strong pipeline of biosimilars and complex generics. With an integrated lab-to-patient model, Biocon combines research and development, manufacturing, and commercial capabilities to ensure reliable and scalable access to medicines. Supported by seven manufacturing sites, three R&D facilities, 18 global offices, and a workforce of over 9,500 employees, Biocon has also been recognized in the S&P Global Sustainability Yearbook 2026 for the fourth consecutive year, reflecting its commitment to sustainable and responsible growth.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
